(Q53931966)

22 May 2018

title

Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy. (English)

1 reference

22 May 2018

author name string

Shin DH

1

1 reference

22 May 2018

Glover BK

2

1 reference

22 May 2018

Cha SC

3

1 reference

22 May 2018

Kim YY

4

1 reference

22 May 2018

Kim C

5

1 reference

22 May 2018

Nguyen KD

6

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 May 1999

1 reference

22 May 2018

American Journal of Ophthalmology

published in

1 reference

22 May 2018

volume

127

1 reference

22 May 2018

issue

5

1 reference

22 May 2018

page(s)

511-515

1 reference

22 May 2018

The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Short-term Effects of Unilateral 1% Apraclonidine Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Pharmacological advances in the treatment of glaucoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Long term effect of apraclonidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Clinical experience with the long-term use of 1% apraclonidine. Incidence of allergic reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

The efficacy of apraclonidine as an adjunct to timolol therapy. Apraclonidine Adjunctive Therapy Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Apraclonidine. A one-week dose-response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Brimonidine tartrate: a one-month dose response study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

The role of brimonidine in the treatment of open-angle glaucoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Effects of brimonidine on aqueous humor dynamics in human eyes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2898%2900450-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9394(98)00450-4

1 reference

22 May 2018

1 reference

22 May 2018